Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Breast Cancer. 2016 Nov;23(6):830-843. Epub 2015 Oct 14.

2.

Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.

Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Endo Y, Hosoda M, Doihara H, Miyoshi S, Yamashita H; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Breast Cancer Res. 2016 Jul 2;18(1):73. doi: 10.1186/s13058-016-0731-3.

3.

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

Ma CX, Bose R, Ellis MJ.

Adv Exp Med Biol. 2016;882:125-54. doi: 10.1007/978-3-319-22909-6_5. Review.

PMID:
26987533
4.

Factors predicting late recurrence for estrogen receptor-positive breast cancer.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J.

J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12.

Supplemental Content

Loading ...
Support Center